{"id":82868,"date":"2026-07-14T15:18:09","date_gmt":"2026-07-14T15:18:09","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/82868\/"},"modified":"2026-07-14T15:18:09","modified_gmt":"2026-07-14T15:18:09","slug":"levi-korsinsky-notifies-investors-of-pending","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/82868\/","title":{"rendered":"Levi & Korsinsky Notifies Investors of Pending"},"content":{"rendered":"

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) — AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform trial of Wainua failed to meet its primary endpoint in ATTR cardiomyopathy. If you held AZN and lost money, you are encouraged to\u00a0check your eligibility to recover losses now<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n

The CARDIO-TTransform study had been described as the largest trial in the ATTR cardiomyopathy population and was positioned as a key driver toward the Company’s stated “$80 billion 2030 ambition.” On the July 29, 2025 earnings call, CEO Pascal Soriot told investors that the 2025 Phase III readouts “have the combined potential to generate well over $10 billion in peak-year revenue on a risk-adjusted basis.” Executive Vice-President of the the BioPharmaceuticals Business Unit, Ruud Dobber, described the CARDIO-TTRansform readout as having “the potential to address key questions regarding the optimal use of silencers and stabilizers.”<\/p>\n

The investigation concerns whether AstraZeneca made materially false or misleading statements to investors prior to the July 9, 2026 disclosure.<\/p>\n

Investors who purchased AZN shares and suffered losses are encouraged to submit your AZN loss details today<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.<\/p>\n

Frequently Asked Questions About the AZN Investigation<\/p>\n

Q: How much did AZN stock drop? A: Shares fell approximately 8.4% premarket, erasing significant market value, after the Company disclosed that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint. Investors who purchased shares and suffered losses may be eligible to seek compensation.<\/p>\n

Q: What is the AZN investigation about? A: A securities investigation is pending concerning AstraZeneca (NYSE: AZN) regarding potentially materially false or misleading statements. Shares fell more than 8% after the Company disclosed the CARDIO-TTransform trial failure, causing losses for shareholders.<\/p>\n

Q: Who is eligible to participate in the AZN investigation? A: Investors who purchased AZN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.<\/p>\n

Q: What if I already sold my AZN shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AZN and sold at a loss may still participate in the investigation.<\/p>\n

Q: What if my AZN losses are small — is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.<\/p>\n

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.<\/p>\n

Q: What do AZN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>
Tel: (212) 363-7500
Fax: (212) 363-7171<\/p>\n

Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) — AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on…\n","protected":false},"author":2,"featured_media":82869,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,32803,30242,30243,36639,36640],"class_list":["post-82868","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-class-action","tag-levi-korsinsky","tag-llp","tag-stock-drop","tag-stock-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116919003494388426","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/82868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=82868"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/82868\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/82869"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=82868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=82868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=82868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}